DUBLIN, Jan. 2, 2025
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that
its Chief Executive Officer, Richard
Pops, will provide a corporate overview and update at the
43rd Annual J.P. Morgan Healthcare Conference. The
presentation will take place on Wednesday,
Jan. 15, 2025 at 11:15 a.m.
PST (2:15 p.m.
EST/7:15 p.m. GMT), followed
by a question and answer session. The live webcast may be accessed
under the Investors tab on www.alkermes.com and will be archived
for 14 days.
About Alkermes plc
Alkermes plc is a global
biopharmaceutical company that seeks to develop innovative
medicines in the field of neuroscience. The company has a portfolio
of proprietary commercial products for the treatment of alcohol
dependence, opioid dependence, schizophrenia and bipolar I
disorder, and a pipeline of clinical and preclinical candidates in
development for neurological disorders, including narcolepsy and
idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate
office and research and development center in Massachusetts and a manufacturing facility in
Ohio. For more information, please
visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original
content:https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341500.html
